AbCellera Biologics Inc. (NASDAQ:ABCL) is considered one of the top high-return penny stocks to buy, with Leerink Partners giving it an ‘Outperform’ rating and a $5 price target on July 7. The company has shifted focus from an antibody discovery platform to developing its internal pipeline.

Leerink Partners is optimistic about AbCellera’s upcoming programs, including ABCL575 and ABCL635, set to enter Phase 1 clinical trials in the third quarter of 2025. The research firm believes these programs could bring significant value to the company in the long term.

AbCellera’s existing antibody discovery collaborations are expected to provide long-term value through milestone payments and royalties. The company’s pivot towards a pipeline focused on validated targets is seen as a strategic move to leverage its antibody capabilities effectively.

AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company that specializes in discovering and developing antibody-based medicines. It uses an AI-powered technology platform to analyze natural immune systems and identify potential antibody-based drugs for development.

While AbCellera shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk. Investors seeking undervalued AI stocks can explore options that may benefit from current economic trends and tariffs.

Read more at Yahoo Finance: Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot